Interestingly, it has been observed that in High Grade Serous Ovarian Cancer (HGSOC) amplification of cyclin E1 (CCNE1) is associated with resistance to platinum-based chemotherapies [50], suggesting that targeting the cell cycle in these patients could represent an effective therapeutic approach. The gene discussed is CCNE1; the disease is ovarian serous adenocarcinoma.